Pamela Crilley, DO

The paradigm for management of relapsed myeloma is evolving rapidly with a plethora of treatment options based on results of clinical trials. One explosive area of scientific and clinical research is the investigation of chimeric antigen receptor T-cell therapy.

Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.